The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI

The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI

Summary: Clostridium difficile infection (CDI) is an enteric bacterial disease that is increasing in prevalence worldwide. C. difficile capitalizes on gut inflammation and microbiome dysbiosis to establish infection, with symptoms ranging from watery diarrhea to toxic megacolon. We reported that the...

Full description

Bibliographic Details
Main Authors: Megan Garland, Andrew J. Hryckowian, Martina Tholen, Kristina Oresic Bender, William W. Van Treuren, Sebastian Loscher, Justin L. Sonnenburg, Matthew Bogyo
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:Cell Reports Medicine
Subjects:
ebselen
microbiome diversity
antibitoic treatment
vancomycin
clostridium difficile
microbiome recovery
Online Access:http://www.sciencedirect.com/science/article/pii/S2666379120300057

Similar Items

Similar Items